Raku Co..Ltd (4154) AI Stock Analysis

Raku Co..Ltd

(TPEx:4154)

Select Model

Rating:37Underperform

Price Target:TWD 10.00▼(-6.98% Downside)

Action:initiatedcoverage

Date:11/10/26

The stock scores at the absolute minimum of 37, reflecting a company in severe financial distress. The most significant factor is the fundamental collapse of its operations, with revenue imploding and massive cash burn rapidly consuming the company's only strength—a low-debt balance sheet. This is compounded by a bearish technical trend with the stock trading below all major moving averages and no supportive valuation metrics. The company is in a critical survival phase with no positive catalysts evident.

Positive Factors

Low LeverageMinimal debt and very low debt-to-equity ratios provide financial flexibility despite operating weakness. This reduces balance-sheet pressure, limits interest-related burdens, and may give management more capacity to fund restructuring or pursue recovery without relying heavily on additional borrowing.

Negative Factors

Persistent UnprofitabilityPersistent net losses and negative operating results point to a business model that has not yet converted activity into sustainable earnings. Negative gross profit in 2024–2025 is especially concerning because it indicates overall selling economics were unfavorable before operating expenses, making recovery more difficult.

Raku Co..Ltd (4154) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 418.45M
Dividend Yield: ―
Average Volume (3M): 16.22K
Price to Earnings (P/E): -15.0
Beta (1Y): 0.07
Revenue Growth: 49.97%
EPS Growth: 76.21%
Country: TW
Employees: 75
Sector: General
Sector Strength: 55
Industry: Beverages - Non-Alcoholic

Raku Co..Ltd Business Overview & Revenue Model

Company Description

Raku Co., Ltd operates a diverse business portfolio, with its boutique accessories division serving customers across Malaysia, Singapore, China, Taiwan, Thailand, Europe, and other global markets. The company's operations are structured into multiple...

Raku Co..Ltd Financial Statement Overview

Summary

Financial performance is critically weak. The income statement shows a collapsed revenue base and massive gross and net losses, the cash flow statement reveals unsustainable cash burn, and the only mitigating factor is a low-debt balance sheet which is rapidly eroding. The overall financial health is in a survival phase.

Income Statement

8Very Negative

Balance Sheet

65Positive

Cash Flow

5Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	29.80M	26.76M	41.37M	279.34M	439.56M	400.71M
Gross Profit	4.29M	-19.89M	-49.08M	-43.43M	41.17M	18.03M
EBITDA	-15.04M	-46.81M	-101.57M	-70.56M	-1.30M	-55.52M
Net Income	-38.42M	-60.57M	-124.79M	-108.82M	-34.94M	-68.87M
Balance Sheet
Total Assets	395.12M	372.79M	457.89M	485.65M	845.82M	677.28M
Cash, Cash Equivalents and Short-Term Investments	67.03M	73.49M	163.44M	119.71M	226.90M	212.73M
Total Debt	91.67M	7.10M	94.30M	5.85M	207.04M	90.24M
Total Liabilities	144.31M	136.87M	223.44M	242.92M	477.32M	279.52M
Stockholders Equity	237.65M	222.44M	221.24M	213.36M	317.12M	331.34M
Cash Flow
Free Cash Flow	-37.77M	-68.89M	-49.32M	48.01M	-105.30M	-183.53M
Operating Cash Flow	-36.64M	-68.19M	-38.07M	56.40M	-7.46M	5.31M
Investing Cash Flow	-73.55M	-35.65M	-8.12M	49.08M	-104.51M	-190.53M
Financing Cash Flow	28.87M	-11.30M	87.64M	-184.75M	101.17M	238.65M

Raku Co..Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4154 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4192	46Neutral	TWD 563.91M	-0.01	―	―	-1.68%	-5.45%
TW:4154	37Underperform	TWD 420.37M	-15.00	―	―	49.97%	76.21%
TW:1781	35Underperform	TWD 407.71M	-8.04	―	―	-12.12%	-17.29%

* General Sector Average

Performance Comparison

TW:4154 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4154	Raku Co..Ltd	10.75	-5.75	-34.85%
TW:1781	Health & Life Co., Ltd.	8.60	-3.40	-28.33%
TW:4192	SynCore Biotechnology Co., Ltd.	15.95	-9.65	-37.70%
TW:6549	TaiwanJ Pharmaceuticals Co., Ltd.	6.25	-1.61	-20.48%
TW:6621	Unipharma Co., Ltd.	12.00	-0.20	-1.64%
TW:7891	BoYen Therapeutics, Inc.	23.45	-8.00	-25.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Raku Co..Ltd AI Stock Analysis